Viet Nam, 2015

Global Vaccine Action Plan (GVAP) and Regional framework indicators

Polio-free status sustained: Yes
Country achieved MNT elimination: Yes
Country verified for measles elimination: No
Seroprevalence of chronic hepatitis B infection reduced to < 1% in 5 year olds by 2017: 2.2%
At least one new or underutilized vaccine introduced since 2010*: Yes
DTP3 national immunization coverage ≥ 95% by 2020: 97%
DTP3 coverage ≥ 90% in at least 90% of districts (proportion of districts with ≥ 90% coverage): Yes (91.4%)
Sustained DTP3 coverage ≥ 95% for three or more years: No
DTP dropout rate < 5%: 1.42%

Non-polio AFP rate = incidence per 100,000 under 15 years; % adequate specimens = % of AFP cases with 2 specimens within 14 days of paralysis onset

Population

<table>
<thead>
<tr>
<th>Source of data for NIP target</th>
<th>Registered population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>91 583 000</td>
</tr>
<tr>
<td>Births</td>
<td>1 753 504</td>
</tr>
<tr>
<td>NIP target &lt; 1 year (surviving infants)</td>
<td>1 753 504</td>
</tr>
<tr>
<td>JRF</td>
<td>93 447 601</td>
</tr>
<tr>
<td>UN*</td>
<td>1 558 522</td>
</tr>
</tbody>
</table>

Finance

<table>
<thead>
<tr>
<th>Gross national income per capita* (US $)</th>
<th>$ 1980</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of routine immunization - funded by government</td>
<td>Yes</td>
</tr>
<tr>
<td>% of routine immunization - funded by government</td>
<td>51%</td>
</tr>
<tr>
<td>Eligible for GAVI support</td>
<td>Yes (transitioning)</td>
</tr>
</tbody>
</table>

Reported cases of selected vaccine preventable diseases

<table>
<thead>
<tr>
<th>Year</th>
<th>Acute flaccid paralysis (AFP)</th>
<th>Measles</th>
<th>Rubella</th>
<th>Congenital rubella syndrome (CRS)</th>
<th>Neonatal tetanus</th>
<th>Total tetanus</th>
<th>Diphtheria</th>
<th>Pertussis</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>1.7</td>
<td>750</td>
<td>8.4</td>
<td>7259</td>
<td>189</td>
<td>186</td>
<td>0.2</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>97%</td>
<td>0.1</td>
<td>1.8</td>
<td>0.0</td>
<td>13</td>
<td>0.0</td>
<td>105</td>
<td>0.1</td>
</tr>
<tr>
<td>2012</td>
<td>1.7</td>
<td>578</td>
<td>6.4</td>
<td>185</td>
<td>92</td>
<td>39</td>
<td>0.0</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>97%</td>
<td>0.1</td>
<td>2.1</td>
<td>0.0</td>
<td>253</td>
<td>0.3</td>
<td>98</td>
<td>0.1</td>
</tr>
<tr>
<td>2013</td>
<td>1.9</td>
<td>1123</td>
<td>12.2</td>
<td>54</td>
<td>3</td>
<td>46</td>
<td>0.0</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>97%</td>
<td>0.0</td>
<td>0.6</td>
<td>0.0</td>
<td>306</td>
<td>0.3</td>
<td>54</td>
<td>0.1</td>
</tr>
<tr>
<td>2014</td>
<td>1.6</td>
<td>15 033</td>
<td>162.4</td>
<td>59</td>
<td>1</td>
<td>34</td>
<td>0.0</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>97%</td>
<td>0.0</td>
<td>0.6</td>
<td>0.0</td>
<td>244</td>
<td>0.3</td>
<td>90</td>
<td>0.1</td>
</tr>
<tr>
<td>2015</td>
<td>1.7</td>
<td>256</td>
<td>2.7</td>
<td>798</td>
<td>8.5</td>
<td>4</td>
<td>15</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>96%</td>
<td>0.0</td>
<td>0.4</td>
<td>0.0</td>
<td>360</td>
<td>0.4</td>
<td>309</td>
<td>0.3</td>
</tr>
</tbody>
</table>

Invasive bacterial disease, rotavirus and Japanese encephalitis

<table>
<thead>
<tr>
<th>Year</th>
<th>Surveillance system type</th>
<th>Confirmed cases</th>
<th>Surveillance system type</th>
<th>Confirmed cases</th>
<th>Surveillance system type</th>
<th>Confirmed cases</th>
<th>Surveillance system type</th>
<th>Confirmed cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>Sentinel (4 sites)</td>
<td>1305</td>
<td>Sentinel (8 sites)</td>
<td>224</td>
<td>Sentinel (3 sites)</td>
<td>Hib - 15 Pneumo - 30 Meningo - 3</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>Sentinel (4 sites)</td>
<td>936</td>
<td>Sentinel (8 sites)</td>
<td>421</td>
<td>Sentinel (3 sites)</td>
<td>Hib - 7 Pneumo - 45 Meningo - 7</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>Sentinel (4 sites)</td>
<td>849</td>
<td>Sentinel (8 sites)</td>
<td>374</td>
<td>Sentinel (3 sites)</td>
<td>Hib - 3 Pneumo - 58 Meningo - 3</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

Confirmed measles cases by month of onset 2011–2015

Confirmed measles cases by age group and vaccination status, 2014–2015
### Immunization schedule

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>BCG</th>
<th>DTP-Hib-HepB</th>
<th>DTP</th>
<th>M2, M3, M4</th>
<th>Measles</th>
<th>M9, M18</th>
<th>TT</th>
<th>PW, +M1, +M6, +Y1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>B</td>
<td>DTP</td>
<td>M18</td>
<td>OPV</td>
<td>M2, M3, M4</td>
<td>MR</td>
<td>M18</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B=birth, W=week, M=month, Y=year

### Planning

- **Multi-year plan (MYP):** Yes (2016-2020)
- **Annual workplan for immunization activities:** Yes
- **Updated wild poliovirus importation and cVDPV response plan:** Yes

### NIP priority needs

No data

### Delivery of immunization services

- **% of population served by outreach:** 10%
- **No. (%) of districts with DTP3 coverage < 80%:** 24 (3%)
- **No. (%) of districts with DTP3 coverage ≥ 90%:** 646 (91%)
- **No. (%) of districts with MCV1 coverage < 80%:** 17 (2%)
- **No. (%) of districts with MCV1 coverage ≥ 90%:** 673 (95%)
- **No. (%) of districts with DTP drop-out > 10%:** 35 (5%)
- **No. (%) of districts with DTP1 – MCV1 drop-out > 10%:** 52 (7%)

### School-based Immunization

- **Is there a school entry requirement?** No
- **If no, do schools check immunization status at enrolment?** No
- **What vaccines are required/checked?**
- **At what school level/year?**
- **Is routine vaccination given at school?** No
- **Which vaccination?**
- **If yes, is this part of a comprehensive school-health program that delivers other health interventions?**

### Safe Immunization

- **% districts using auto-disable syringes:** 100%
- **System to monitor AEFI:** Yes
- **Number of AEFI:** 48
- **Injection safety policy implemented:** Yes
- **Disposal methods:** Incineration, Open burning, Burial
- **Injection safety review**

### Number of children in districts, by category of DTP3 coverage, 2014–2015

- **2014:**
  - <50%: 32,691
  - 50-79%: 91,011
  - 80-89%: 120,277
  - ≥90%: 7,545
- **2015:**
  - <50%: 23,900
  - 50-79%: 72,219
  - 80-89%: 54,045
  - ≥90%: 1,579

### Reports of immunization coverage, 2006–2015

- **BCG:**
  - 2006: 32,691
  - 2007: 91,011
  - 2008: 120,277
  - 2009: 7,545
- **DTP3:**
  - 2006: 23,900
  - 2007: 72,219
  - 2008: 54,045
  - 2009: 1,579

### Measles and rubella elimination

- **Confirmed measles case rate* (per 1 million population):** 3.1
- **Year of MCV1 introduction:** 1981
- **Confirmed rubella case rate* (per 1 million population):** 9.2
- **Year of MCV2 introduction:** 2006
- **Discarded as non-measles rate* (Target: ≥ 2 per 100 000 population):** 2.0
- **Year of RCV introduction:** 2011
- **% suspected cases with adequate specimens* (Target: ≥ 80%):** 55.4%
- **Surveillance conducted for CRS:** Yes (Sentinel)
- **Imported measles cases*:** 0
- **Antigens, year and target population of last SIA:** MR - 2014-2015 (1-14 yrs)
- **There were no differences in vaccine coverages between boys and girls.**

### Hepatitis B control

- **Year HepB3 vaccine introduced nationwide:** 1997
- **Year HepB birth dose introduced:** 2005
- **HepB birth dose (within 24 hours) coverage:** 69.8%
- **HepB birth dose (within and after 24 hours) coverage:** 74.3%

---

* Data from measles monthly country reports to WHO